Literature DB >> 27076228

Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature.

Slavé Petrovski1, Roberta E Parrott2, Joseph L Roberts2, Hongxiang Huang2,3, Jialong Yang2, Balachandra Gorentla2, Talal Mousallem2,4, Endi Wang5, Martin Armstrong6, Duncan McHale6, Nancie J MacIver7,8, David B Goldstein1, Xiao-Ping Zhong2,8, Rebecca H Buckley9,10.   

Abstract

The purpose of this research was to use next generation sequencing to identify mutations in patients with primary immunodeficiency diseases whose pathogenic gene mutations had not been identified. Remarkably, four unrelated patients were found by next generation sequencing to have the same heterozygous mutation in an essential donor splice site of PIK3R1 (NM_181523.2:c.1425 + 1G > A) found in three prior reports. All four had the Hyper IgM syndrome, lymphadenopathy and short stature, and one also had SHORT syndrome. They were investigated with in vitro immune studies, RT-PCR, and immunoblotting studies of the mutation's effect on mTOR pathway signaling. All patients had very low percentages of memory B cells and class-switched memory B cells and reduced numbers of naïve CD4+ and CD8+ T cells. RT-PCR confirmed the presence of both an abnormal 273 base-pair (bp) size and a normal 399 bp size band in the patient and only the normal band was present in the parents. Following anti-CD40 stimulation, patient's EBV-B cells displayed higher levels of S6 phosphorylation (mTOR complex 1 dependent event), Akt phosphorylation at serine 473 (mTOR complex 2 dependent event), and Akt phosphorylation at threonine 308 (PI3K/PDK1 dependent event) than controls, suggesting elevated mTOR signaling downstream of CD40. These observations suggest that amino acids 435-474 in PIK3R1 are important for its stability and also its ability to restrain PI3K activity. Deletion of Exon 11 leads to constitutive activation of PI3K signaling. This is the first report of this mutation and immunologic abnormalities in SHORT syndrome.

Entities:  

Keywords:  Hyper IgM syndrome; PIK3R1 splice site mutations; SHORT syndrome; lymphadenopathy; mTOR pathway; next generation sequencing; short stature

Mesh:

Substances:

Year:  2016        PMID: 27076228      PMCID: PMC5690581          DOI: 10.1007/s10875-016-0281-6

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  30 in total

1.  Autosomal dominant PIK3R1 mutations cause SHORT syndrome.

Authors:  B K Chung; W T Gibson
Journal:  Clin Genet       Date:  2013-09-23       Impact factor: 4.438

2.  Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.

Authors:  M Elgizouli; D M Lowe; C Speckmann; D Schubert; J Hülsdünker; Z Eskandarian; A Dudek; A Schmitt-Graeff; J Wanders; S F Jørgensen; B Fevang; U Salzer; A Nieters; S Burns; B Grimbacher
Journal:  Clin Exp Immunol       Date:  2015-11-09       Impact factor: 4.330

3.  SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling.

Authors:  Kishan Kumar Chudasama; Jonathon Winnay; Stefan Johansson; Tor Claudi; Rainer König; Ingfrid Haldorsen; Bente Johansson; Ju Rang Woo; Dagfinn Aarskog; Jørn V Sagen; C Ronald Kahn; Anders Molven; Pål Rasmus Njølstad
Journal:  Am J Hum Genet       Date:  2013-06-27       Impact factor: 11.025

4.  Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.

Authors:  Carrie L Lucas; Hye Sun Kuehn; Fang Zhao; Julie E Niemela; Elissa K Deenick; Umaimainthan Palendira; Danielle T Avery; Leen Moens; Jennifer L Cannons; Matthew Biancalana; Jennifer Stoddard; Weiming Ouyang; David M Frucht; V Koneti Rao; T Prescott Atkinson; Anahita Agharahimi; Ashleigh A Hussey; Les R Folio; Kenneth N Olivier; Thomas A Fleisher; Stefania Pittaluga; Steven M Holland; Jeffrey I Cohen; Joao B Oliveira; Stuart G Tangye; Pamela L Schwartzberg; Michael J Lenardo; Gulbu Uzel
Journal:  Nat Immunol       Date:  2013-10-28       Impact factor: 25.606

Review 5.  Synergy in activating class I PI3Ks.

Authors:  John E Burke; Roger L Williams
Journal:  Trends Biochem Sci       Date:  2015-01-05       Impact factor: 13.807

6.  Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K.

Authors:  Mary Ellen Conley; A Kerry Dobbs; Anita M Quintana; Amma Bosompem; Yong-Dong Wang; Elaine Coustan-Smith; Amber M Smith; Elena E Perez; Peter J Murray
Journal:  J Exp Med       Date:  2012-02-20       Impact factor: 14.307

7.  Genic intolerance to functional variation and the interpretation of personal genomes.

Authors:  Slavé Petrovski; Quanli Wang; Erin L Heinzen; Andrew S Allen; David B Goldstein
Journal:  PLoS Genet       Date:  2013-08-22       Impact factor: 5.917

8.  Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome.

Authors:  Sven Kracker; James Curtis; Mohammad A A Ibrahim; Anna Sediva; Jon Salisbury; Vit Campr; Marianne Debré; J David M Edgar; Kohsuke Imai; Capucine Picard; Jean-Laurent Casanova; Alain Fischer; Sergey Nejentsev; Anne Durandy
Journal:  J Allergy Clin Immunol       Date:  2014-04-01       Impact factor: 10.793

Review 9.  Signaling by the phosphoinositide 3-kinase family in immune cells.

Authors:  Klaus Okkenhaug
Journal:  Annu Rev Immunol       Date:  2013-01-16       Impact factor: 28.527

10.  The Mouse Genome Database: integration of and access to knowledge about the laboratory mouse.

Authors:  Judith A Blake; Carol J Bult; Janan T Eppig; James A Kadin; Joel E Richardson
Journal:  Nucleic Acids Res       Date:  2013-11-26       Impact factor: 16.971

View more
  18 in total

Review 1.  Immune Dysregulation and Disease Pathogenesis due to Activating Mutations in PIK3CD-the Goldilocks' Effect.

Authors:  Stuart G Tangye; Julia Bier; Anthony Lau; Tina Nguyen; Gulbu Uzel; Elissa K Deenick
Journal:  J Clin Immunol       Date:  2019-03-25       Impact factor: 8.317

2.  Autosomal Recessive Agammaglobulinemia Due to a Homozygous Mutation in PIK3R1.

Authors:  Paoyun Tang; Julia E M Upton; Michelle A Barton-Forbes; Marina I Salvadori; Meghan P Clynick; April K Price; Sharan L Goobie
Journal:  J Clin Immunol       Date:  2017-11-25       Impact factor: 8.317

Review 3.  Targeted Therapy with Biologicals and Small Molecules in Primary Immunodeficiencies.

Authors:  Ottavia Maria Delmonte; Luigi Daniele Notarangelo
Journal:  Med Princ Pract       Date:  2019-10-10       Impact factor: 1.927

4.  Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway.

Authors:  Ryo Kushi; Yushi Hirota; Wataru Ogawa
Journal:  Diabetol Int       Date:  2020-07-15

5.  New classification and diagnostic criteria for insulin resistance syndrome.

Authors:  Wataru Ogawa; Eiichi Araki; Yasushi Ishigaki; Yushi Hirota; Hiroshi Maegawa; Toshimasa Yamauchi; Tohru Yorifuji; Hideki Katagiri
Journal:  Diabetol Int       Date:  2022-01-31

6.  PI3K Isoforms in B Cells.

Authors:  Elissa K Deenick; Julia Bier; Anthony Lau
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

Review 7.  PI3Kδ and primary immunodeficiencies.

Authors:  Carrie L Lucas; Anita Chandra; Sergey Nejentsev; Alison M Condliffe; Klaus Okkenhaug
Journal:  Nat Rev Immunol       Date:  2016-09-12       Impact factor: 53.106

Review 8.  Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.

Authors:  Jean-Marie Carpier; Carrie L Lucas
Journal:  Front Immunol       Date:  2018-01-16       Impact factor: 7.561

Review 9.  Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.

Authors:  Gillian L Dornan; John E Burke
Journal:  Front Immunol       Date:  2018-03-19       Impact factor: 7.561

Review 10.  Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.

Authors:  Alison M Condliffe; Anita Chandra
Journal:  Front Immunol       Date:  2018-03-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.